These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 518073)
1. Alafosfalin, a new inhibitor of cell wall biosynthesis: in vitro activity against urinary isolates in Japan and potentiation with beta-lactams. Maruyama HB; Arisawa M; Sawada T Antimicrob Agents Chemother; 1979 Oct; 16(4):444-51. PubMed ID: 518073 [TBL] [Abstract][Full Text] [Related]
2. In vitro potentiation of cephalosporins by alafosfalin against urinary tract bacteria. Arisawa M; Ohshima J; Ohsawa E; Maruyama HB Antimicrob Agents Chemother; 1982 May; 21(5):706-10. PubMed ID: 7103452 [TBL] [Abstract][Full Text] [Related]
3. Antibacterial properties of alafosfalin combined with cephalexin. Atherton FR; Hall MJ; Hassall CH; Holmes SW; Lambert RW; Lloyd WJ; Nisbet LJ; Ringrose PS; Westmacott D Antimicrob Agents Chemother; 1981 Oct; 20(4):470-6. PubMed ID: 7044291 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863 [TBL] [Abstract][Full Text] [Related]
5. Phosphonopeptide antibacterial agents related to alafosfalin: design, synthesis, and structure-activity relationships. Atherton FR; Hall MJ; Hassall CH; Holmes SW; Lambert RW; Lloyd WJ; Ringrose PS Antimicrob Agents Chemother; 1980 Dec; 18(6):897-905. PubMed ID: 7016027 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of antimicrobial activity of beta-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan. Ishii Y; Alba J; Kimura S; Shiroto K; Yamaguchi K Int J Antimicrob Agents; 2005 Apr; 25(4):296-301. PubMed ID: 15784308 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity and beta-lactamase stability of a new penem, CGP 31608. Neu HC; Chin NX; Neu NM Antimicrob Agents Chemother; 1987 Apr; 31(4):558-69. PubMed ID: 3496845 [TBL] [Abstract][Full Text] [Related]
9. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. Livermore DM; Mushtaq S; Warner M; Woodford N J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835 [TBL] [Abstract][Full Text] [Related]
10. [In vitro antibacterial activity of a new parenteral penem, sulopenem]. Yoshida T; Tateda E; Hiramatsu K; Yokota T Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624 [TBL] [Abstract][Full Text] [Related]
11. Activity of a peptidyl prodrug, alafosfalin, against anaerobic bacteria. Grappel SF; Giovenella AJ; Nisbet LJ Antimicrob Agents Chemother; 1985 Jun; 27(6):961-3. PubMed ID: 4026269 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of BRL 42715, a beta-lactamase-inhibiting penem. Qadri SM; Ueno Y; Burdette M; Kroschinsky R; Almodovar E Chemotherapy; 1991; 37(6):398-404. PubMed ID: 1760938 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş Z; Kayacan C; Oncul O Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508 [TBL] [Abstract][Full Text] [Related]
15. Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital. Jarlier V; Bismuth R; Nicolas MH; Nguyen J; Truffot C; Grosset J J Antimicrob Chemother; 1984 Sep; 14 Suppl B():59-65. PubMed ID: 6501135 [TBL] [Abstract][Full Text] [Related]
16. Synergistic antibacterial activity between L-norvalyl-L-1-aminoethylphosphonic acid and nocardicin A. Angehrn P; Hall MJ; Lloyd WJ; Westmacott D Antimicrob Agents Chemother; 1984 May; 25(5):607-11. PubMed ID: 6428312 [TBL] [Abstract][Full Text] [Related]
17. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343. Medeiros AA; Hare R; Papa E; Adam C; Miller GH J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602 [TBL] [Abstract][Full Text] [Related]
18. Alafosfalin, a new synthetic antibacterial compound. Hahn FE Naturwissenschaften; 1981 Feb; 68(2):90. PubMed ID: 7219565 [No Abstract] [Full Text] [Related]
19. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]